UBS Initiates Coverage On IDEAYA Biosciences with Buy Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
UBS analyst David Dai has initiated coverage on IDEAYA Biosciences with a Buy rating and set a price target of $50.
October 24, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS has initiated coverage on IDEAYA Biosciences with a Buy rating and a price target of $50, indicating a positive outlook for the stock.
The initiation of coverage by UBS with a Buy rating and a $50 price target suggests a positive sentiment from a reputable financial institution, likely leading to increased investor interest and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100